Pacira BioSciences, Inc.

Equities

PCRX

US6951271005

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-09-13 pm EDT 5-day change 1st Jan Change
13.11 USD +2.99% Intraday chart for Pacira BioSciences, Inc. -10.69% -61.14%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Pacira Biosciences, Inc. Announces Board Changes CI
Truist Securities Downgrades Pacira BioSciences to Sell From Buy, Adjusts Price Target to $8 From $30 MT
Pacira Biosciences Challenged by Court Ruling on Exparel, 'Uncertain' Prospects, RBC Say MT
Sector Update: Health Care Stocks Flat to Higher Pre-bell Monday MT
RBC Capital Downgrades Pacira BioSciences to Sector Perform From Outperform, Cuts Price Target to $14 From $37 MT
RBC Downgrades Pacira BioSciences to Sector Perform From Outperform, Adjusts Price Target to $14 From $37 MT
JPMorgan Downgrades Pacira BioSciences to Underweight From Overweight, Adjusts Price Target to $10 From $45 MT
Raymond James Downgrades Pacira BioSciences to Market Perform From Outperform MT
Piper Sandler Downgrades Pacira BioSciences to Neutral From Overweight, Adjusts Price Target to $11 From $42 MT
Pacira BioSciences Considers Legal Options After Federal Judge Rules Against Patent MT
RBC Lowers Price Target on Pacira BioSciences to $37 From $42, Keeps Outperform Rating MT
Transcript : Pacira BioSciences, Inc., Q2 2024 Earnings Call, Jul 30, 2024
Tranche Update on Pacira BioSciences, Inc.'s Equity Buyback Plan announced on May 7, 2024. CI
Pacira BioSciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 CI
Earnings Flash (PCRX) PACIRA BIOSCIENCES Reports Q2 Revenue $178M, vs. Street Est of $173.7M MT
Pacira BioSciences, Inc. Reiterates Financial Guidance for the Full Year 2024 CI
Truist Cuts Price Target on Pacira BioSciences to $30 From $45, Keeps Buy Rating MT
Pacira BioSciences, Inc. Announces Centers for Medicare and Medicaid Propose New Reimbursement for EXPAREL in All Outpatient Surgical Environments Beginning January 1, 2025 CI
RBC Cuts Price Target on Pacira BioSciences to $42 From $45, Keeps Outperform Rating MT
Barclays Downgrades Pacira BioSciences to Equalweight From Overweight, Adjusts Price Target to $25 From $38 MT
Pacira BioSciences Shares Tumble as FDA Approves Exparel Generic DJ
Pacira BioSciences, Inc.(NasdaqGS:PCRX) added to Russell Small Cap Comp Value Index CI
Pacira BioSciences, Inc.(NasdaqGS:PCRX) added to Russell 2500 Value Index CI
Pacira BioSciences, Inc.(NasdaqGS:PCRX) added to Russell 3000 Value Index CI
Pacira BioSciences, Inc.(NasdaqGS:PCRX) added to Russell 2000 Value Index CI
Chart Pacira BioSciences, Inc.
More charts
Logo Pacira BioSciences, Inc.
Pacira BioSciences, Inc. is a holding company for Pacira Pharmaceuticals, Inc. The Company's non-opioid treatments include EXPAREL (bupivacaine liposome injectable suspension), which is a long-acting, local analgesic for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), which is an extended-release, intra-articular (IA), corticosteroid injection indicated for OA knee pain, and Iovera, which is a novel handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. EXPAREL is used across multiple orthopedic procedures, including joint reconstruction, shoulder, spine, extremity procedures, and hip fractures. It is developing interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain. Its clinical development programs include PCRX-201, and pMVL-Based Clinical Program.
Employees
712
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
9
Last Close Price
12.73USD
Average target price
18.00USD
Spread / Average Target
+41.40%
Consensus
  1. Stock Market
  2. Equities
  3. PCRX Stock
  4. News Pacira BioSciences, Inc.
  5. Pacira Biosciences Challenged by Court Ruling on Exparel, 'Uncertain' Prospects, RBC Say
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities. Last hours!
BENEFIT NOW